Journals / Cukurova Medical Journal / 2020 / Cilt: 45 - Sayı: 3

Electron and light microscopic evaluation of effects of the Lapatinib on rat ovary and uterus

Lapatinib’in sıçan over ve uterus dokuları üzerine olan etkilerinin ışık ve elektron mikroskobik düzeyde araştırılması

Pages
921–932
Publication Date
2020-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Besides the reduction of estradiol and progesterone levels in experimental groups, structural changes in stromal cells and glands of endometrium, oocyte, granulose cells and interstitial cells of ovaries were observed, and it was observed that these changes were more prominent in high dose group.Conclusion: Drugs that are used in targeted therapies, such as Lapatinib, can cause structural and functional changes in tissues and organs depending on blockage of receptors and targeted signal molecules.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Many drugs, started to be used in targeted anti-cancer treatment as a result of advances in molecular oncology, stop proliferation of tumor cells via interacting with cell receptors and intracellular signaling molecules.
📊
Key Findings & Data:Our study aimed to investigate changes in uterine and ovarian tissues of rats caused by Lapatinib at biochemical, light and electron microscopic levels.Materials and Methods: 24 female Wistar rats were divided into 3 groups, 30 mg/kg and 75 mg/kg Lapatinib to experimental groups, and same amount of distilled water to the control group were applied twice a day by gavage during 14 days.
💡
Conclusion & Impact:Results: Besides the reduction of estradiol and progesterone levels in experimental groups, structural changes in stromal cells and glands of endometrium, oocyte, granulose cells and interstitial cells of ovaries were observed, and it was observed that these changes were more prominent in high dose group.Conclusion: Drugs that are used in targeted therapies, such as Lapatinib, can cause structural and functional changes in tissues and organs depending on blockage of receptors and targeted signal molecules.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:lapatinib · ovary · uterus

Abstract

Purpose: Many drugs, started to be used in targeted anti-cancer treatment as a result of advances in molecular oncology, stop proliferation of tumor cells via interacting with cell receptors and intracellular signaling molecules. Because of physiological functions of these targets, adverse effects develop during therapy. Lapatinib is one of the drugs used in targeted therapies, enters into the cell and inhibits the activity of epidermal growth factor and receptor-linked tyrosine kinase. Our study aimed to investigate changes in uterine and ovarian tissues of rats caused by Lapatinib at biochemical, light and electron microscopic levels.Materials and Methods: 24 female Wistar rats were divided into 3 groups, 30 mg/kg and 75 mg/kg Lapatinib to experimental groups, and same amount of distilled water to the control group were applied twice a day by gavage during 14 days. Blood samples were collected for estradiol, progesterone, FSH and LH serum levels. Uterine and ovarian tissue samples were prepared for light and electron microscopic examinations and evaluated by Jeol JEM 1400 TEM and Olympus BX 50 light microscope. Results: Besides the reduction of estradiol and progesterone levels in experimental groups, structural changes in stromal cells and glands of endometrium, oocyte, granulose cells and interstitial cells of ovaries were observed, and it was observed that these changes were more prominent in high dose group.Conclusion: Drugs that are used in targeted therapies, such as Lapatinib, can cause structural and functional changes in tissues and organs depending on blockage of receptors and targeted signal molecules.

Özet

Amaç: Moleküler onkolojideki gelişmeler sonucunda hedeflenmiş anti-kanser tedavisinde kullanılmaya başlanan birçok ilaç, hücre reseptörleri ve hücre içi sinyal molekülleri ile etkileşerek tümör hücrelerinin çoğalmasını durdurmaktadır. Bu hedeflerin fizyolojik görevleri nedeniyle tedavi sırasında yan etkiler gelişmektedir. Hedefe yönelik tedavide kullanılan ilaçlardan biri olan Lapatinib hücre içine girerek epidermal büyüme faktörü ve reseptörüne bağlı tirozin kinaz aktivitesini inhibe etmektedir. Çalışmamızda Lapatinib’in sıçan uterus ve over dokularında yol açabileceği değişikliklerin biyokimyasal, ışık ve elektron mikroskobik düzeyde incelenmesi amaçlandı. Gereç ve Yöntem: 24 adet Wistar cinsi dişi sıçan 3 gruba ayrılarak, deney gruplarına sırasıyla 30 mg/kg ve 75 mg/kg Lapatinib, kontrol grubuna ise aynı miktarda distile su gavaj yoluyla, günde 2 kez 14 gün boyunca uygulandı. Deney sonunda hayvanlardan kan örnekleri alınarak serum östradiol, progesteron, FSH ve LH seviyeleri ölçüldü. Uterus ve over doku örnekleri ışık ve elektron mikroskobik doku hazırlama yöntemlerine uygun olarak hazırlandı. Dokulardan elde edilen kesitler, Jeol JEM 1400 TEM ve Olympus BX 50 ışık mikroskoplarında değerlendirildi.Bulgular: Deney gruplarına ait sıçanlarda östradiol ve progesteron seviyelerinde azalma yanında ışık ve elektron mikroskobik kesitlerde, endometriyumda stromal hücreler ve bezlerde, overlerde ise oosit, granüloza hücreleri ile interstisyel hücrelerde yapısal değişikliklerin geliştiği ve bu değişikliklerin yüksek doz grubunda daha belirgin olduğu gözlendi.Sonuç: Lapatinib gibi hedefe yönelik tedavilerde kullanılan ilaçların hedeflediği reseptörler ve sinyal moleküllerinin blokajına bağlı olarak bunların kullanıldığı doku ve organların yapı ve fonksiyonlarında değişiklikler gelişebileceği kanaatine varıldı.

🔖

Cite This Article

TOKGÖNÜL, H., KUYUCU, Y., METE, U. (2020). Electron and light microscopic evaluation of effects of the Lapatinib on rat ovary and uterus. Cukurova Medical Journal, Cilt: 45 - Sayı: 3, 921–932. https://ajindex.com/articles/109136

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Kansu E. Hedeflenmiş tedavilerde “hedef” moleküller. ANKEM Derg. 2005;19(Ek 2):112-6
  2. Atalay C. Her2 pozitif meme kanserine cerrahi yaklaşım nasıl olmalı?. Journal of Breast Health. 2010;6:1-4
  3. Öztop İ. Baş boyun tümörlerinde hedefe yönelik tedavi. Uluslararası Hematoloji-Onkoloji Dergisi. 2008;1:46-56
  4. Öztop İ. Küçük hücreli dışı akciğer kanserinde hedefe yönelik tedavi. Uluslararası Hematoloji-Onkoloji Dergisi. 2009;3:184-94
  5. Duvan Cİ, Şatıroğlu H, Berker B, Çetinkaya E, Kahraman K. Yardımla üreme tekniklerinde impantasyon ve gebelik oranlarını etkileyen faktörler. T Klin Jinekol Obst. 2003;13:466-75
  6. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689-708
  7. Chen HX, Cleck JN, Coelho R, Dancey JE. Epidermal growth factor receptor inhibitors: current status and future directions. Curr Probl Cancer. 2009;33:245-94
  8. Küçükzeybek Y, Küçükzeybek BB, Demir C. HER2 pozitif metastatik meme kanserlerinde trastuzumab içeren kemoterapi ile progresyon sonrasında tedavi seçenekleri. Van Tıp Dergisi. 2010;17:164-9
  9. Yazıcı S, Özen H. Böbrek tümörlerinde hedefe yönelik tedavi. Üroonlokoji Bülteni. 2007;3:3-10
  10. Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol. 2006;58:242-56
  11. Giampaglia M, Chiuri VE, Tinelli A, De Laurentiis M, Silvestris N, Lorusso V. Lapatinib in breast cancer: clinical experiences and future perspectives. Cancer Treat Rev. 2010;36:72-9
  12. Kroep JR, Linn SC, Boven E, Bloemendal HJ, Baas J, Mandjes IAM et al. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer. Neth J Med. 2010;68:371-6
  13. Medina PJ, Goodin S. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008;30:1426-46
  14. Tevaarwerk AJ, Kolesar JM. Lapatinib: A smallmolecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor–2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31:2332-48
  15. Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, Manikhas A, Pienkowski T, DeSilvio M et al. A singlearm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology. 2010;79:129-35
  16. Amir E, Ocaña A, Seruga B, Freedman O, Clem